The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer.
 
Satoru Iwasa
Honoraria - Lilly; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Novartis
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Ono Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Lilly; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Shunji Takahashi
Honoraria - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Haeseong Park
Research Funding - Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Gilead Sciences; Incyte; Lilly; Macrogenics; MedImmune; Medivation; Merck; Millennium; Novartis; Pfizer; Puma Biotechnology; Regeneron; Roche; Taiho Pharmaceutical; Vertex
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Shanu Modi
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
 
Yoshikane Nonagase
No Relationships to Disclose
 
Kenji Tamura
Research Funding - Daiichi Sankyo
 
Kensei Yamaguchi
Speakers' Bureau - Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Junji Tsurutani
Honoraria - Chugai Pharma; Eisai; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Asahi Kasei; Eisai
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Javad Shahidi
Employment - Daiichi Sankyo; Lilly
Stock and Other Ownership Interests - Lilly
 
Caleb C. Lee
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo (Inst)
 
Yoshinori Kawaguchi
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)